Molecular Partners (NASDAQ: MOLN) begins MP0317 Phase 2 TACTIC study
Rhea-AI Filing Summary
Molecular Partners reports clinical progress for MP0317, announcing dosing of first patients in the investigator‑initiated, randomized Phase 2 TACTIC proof‑of‑concept study in front‑line advanced biliary tract carcinoma (cholangiocarcinoma). The French multicenter trial plans to enroll 75 patients, with 50 in the experimental arm and 25 in the control arm, testing MP0317 plus standard‑of‑care chemoimmunotherapy (durvalumab plus gemcitabine‑cisplatin) versus standard‑of‑care alone. Nine expert trial sites are activated and patient treatment is ongoing.
MP0317 is described as a FAP‑localized CD40 agonist designed to remodel the tumor microenvironment and is hypothesized to improve 12‑month progression‑free survival compared with standard‑of‑care alone. A data update is expected in 2027, with completion of the study in 2028, and a trial‑in‑progress poster has been accepted for presentation at the ESMO Congress 2026 in Madrid. A completed Phase 1 dose‑escalation study in 46 patients with advanced solid tumors across 9 dose levels showed tumor‑localized CD40 activation and tumor microenvironment remodeling, with results published in Nature Cancer.
Positive
- None.
Negative
- None.
Key Figures
Planned enrollment: 75 patients
Experimental arm size: 50 patients
Control arm size: 25 patients
+5 more
8 metrics
Planned enrollment
75 patients
Target enrollment for the randomized Phase 2 TACTIC trial in France
Experimental arm size
50 patients
Patients receiving MP0317 plus standard-of-care in the TACTIC trial
Control arm size
25 patients
Patients receiving standard-of-care alone in the TACTIC trial
Active trial sites
9 sites
Expert centers activated and recruiting for the TACTIC study
Phase 1 patients treated
46 patients
Number of advanced solid tumor patients in the completed MP0317 Phase 1 study
Phase 1 dose levels
9 dose levels
Dose-escalation cohorts evaluated in the MP0317 Phase 1 trial
Data update timing
2027
Expected timing for a data update from the TACTIC Phase 2 study
Study completion timing
2028
Expected completion year for the MP0317 TACTIC Phase 2 trial
Key Terms
DARPin therapeutics, chemoimmunotherapy, tumor microenvironment, FAP-localized CD40 agonist, +2 more
6 terms
DARPin therapeutics medical
"developing a novel class of custom-built protein drugs known as DARPin therapeutics"
Darpin therapeutics are medicines built from designed ankyrin repeat proteins — small, engineered proteins crafted to stick to specific molecules involved in disease, much like a custom key fitting a lock. They matter to investors because their compact, stable design can make treatments easier and cheaper to manufacture, allow targeting of multiple disease mechanisms, and may offer faster development paths compared with traditional biologic drugs.
chemoimmunotherapy medical
"MP0317 in combination with chemoimmunotherapy in first line treatment"
Chemoimmunotherapy is a cancer treatment approach that combines drugs that directly kill tumor cells with medicines that boost or guide the patient’s immune system to recognize and attack cancer. For investors, it matters because combining these two approaches can change clinical trial outcomes, regulatory paths, potential sales and pricing, and the risk/reward profile of drug candidates much like adding a second player to a team can improve performance but also complicate strategy and costs.
tumor microenvironment medical
"designed to drive immune-mediated remodeling of the tumor microenvironment"
The tumor microenvironment is the immediate area surrounding a cancer cell, made up of nearby cells, blood vessels, and support structures that influence how the cancer grows and spreads. It functions like a bustling neighborhood that can either help or hinder the tumor’s development. For investors, understanding changes in this environment can signal the effectiveness of treatments and potential shifts in a cancer-related market.
FAP-localized CD40 agonist medical
"MP0317, a FAP-localized CD40 agonist designed to drive immune-mediated remodeling"
progression-free survival medical
"hypothesized to improve 12-month progression-free survival rate of patients"
Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.
investigator-initiated Phase 2 proof-of-concept study medical
"dosing of first patients in an investigator-initiated Phase 2 proof-of-concept study"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Molecular Partners (MOLN) announce regarding the MP0317 TACTIC trial?
Molecular Partners announced dosing of the first patients in the randomized Phase 2 TACTIC study of MP0317 for front‑line advanced cholangiocarcinoma, combining MP0317 with standard‑of‑care chemoimmunotherapy and comparing it to standard‑of‑care alone across multiple centers in France.
How is the MP0317 Phase 2 TACTIC trial for MOLN designed and how many patients will it enroll?
The TACTIC study is a randomized, multicenter Phase 2 trial in France aiming to enroll 75 patients. It uses a 2‑to‑1 design, with 50 patients in the experimental arm receiving MP0317 plus standard‑of‑care and 25 patients in the control arm receiving standard‑of‑care alone.
What is the expected timeline for MP0317 Phase 2 TACTIC trial results for Molecular Partners (MOLN)?
A data update from the MP0317 Phase 2 TACTIC trial is expected in 2027, with completion of the study planned for 2028. A trial‑in‑progress poster has also been accepted for presentation at the ESMO Congress 2026 in Madrid.
What is MP0317 and what outcome is it hypothesized to improve in the MOLN TACTIC study?
MP0317 is a FAP‑localized CD40 agonist designed to remodel the tumor microenvironment. In the TACTIC trial, it is hypothesized to improve the 12‑month progression‑free survival rate of patients with advanced cholangiocarcinoma compared with standard‑of‑care treatment alone.
What prior clinical data supports MP0317 for Molecular Partners (MOLN)?
Molecular Partners completed a Phase 1 dose‑escalation study of MP0317 in 46 patients with advanced solid tumors across 9 dose levels. Biomarker analyses showed tumor‑localized CD40 activation and tumor microenvironment remodeling, with results published in the journal Nature Cancer.